Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...

Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

The drug will be made available to people with private health insurance from the start of next year, said Pfizer. Comirnaty sales, meanwhile, are expected to be around $2 billion lower than ...

United States health authorities Monday gave full approval to the COVID-19 vaccine developed by Pfizer-BioNTech, which will now be marketed under the Comirnaty brand. Moderna's drug is expected to ...

Pfizer faces near-term challenges as COVID-19 product sales decline. However, excluding Comirnaty and Paxlovid, revenue grew 12% operationally in full-year 2024. This result demonstrates the ...

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

With the end of the pandemic, sales of Pfizer’s COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 from $56.7 billion in 2022. In 2025, Pfizer’s revenues from ...

The pharmaceutical company Pfizer Friday filed an application before Brazil's National Health Surveillance Agency (Anvisa) for its COVID-19 vaccine named Comirnaty to be cleared for use on ...

That lawsuit has been on hold waiting for the patent board's ruling. Moderna had argued that Pfizer’s vaccine, Comirnaty, uses modified messenger RNA technology that Moderna had patented ...

Pfizer and BioNTech did not deny using mRNA technology that had been patented by Moderna for the development of their Comirnaty COVID-19 vaccine, but argued that a 2020 Moderna press release had ...

"Today's decision has no immediate impact on Pfizer, BioNTech or Comirnaty," BioNTech's spokesperson added. "We continue to believe that EP949 is invalid, and therefore not infringed, and will ...